The tumor suppressor protein p53 is widely implicated in cancer. MDM2, a regulator of cell growth, can inhibit p53 and MDM2-A is one MDM2 splice isoform that is often detected in tumors. Here, Erin Volk, Katja Schuster and colleagues study the role of this truncated protein by creating trans- genic mice that express MDM2-A in normal tissues. Although the mice were not prone to tumor development, heterozygote mice had a shorter life span than wild-type mice and homozygotes died shortly after birth. Studies using MDM2-A mice showed that, in contrast to the cancer-promoting activity of full-length MDM2 protein, MDM2-A activates p53, inhibits growth and enhances cell senescence. This work encourages further exploration of the unique roles of MDM2 variants in tumori-genesis and cell growth.
MDM2 variant found in tumors paradoxically promotes cell death
MDM2 variant found in tumors paradoxically promotes cell death. Dis Model Mech 7 January 2009; 2 (1-2): 1. doi:
Download citation file:
Advertisement
Cited by
New Special Issue: Translating Multiscale Research in Rare Disease. Edited by Monica Justice, Monkol Lek, Karen Liu and Kate Rauen.
This special issue features original Research, Resources & Methods and Review-type articles that aim to interrogate the mechanisms of rare diseases to foster meaningful clinical progress in their diagnosis and treatment.
The role of the International Society for Stem Cell Research (ISSCR) guidelines in disease modelling
The ISSCR provides comprehensive guidelines and standards for using human stem cells in biomedical research. In this Editorial, Cody Juguilon and Joseph Wu discuss how and why these should be incorporated in disease modelling research.
Subject collection: Building advocacy into research
DMM’s series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Biologists @ 100 - join us in Liverpool in March 2025
We are excited to invite you to a unique scientific conference, celebrating the 100-year anniversary of The Company of Biologists, and bringing together our different communities. The conference will incorporate the Spring Meetings of the BSCB and the BSDB, the JEB Symposium Sensory Perception in a Changing World and a DMM programme on antimicrobial resistance. Find out more and register your interest to join us in March 2025 in Liverpool, UK.
Other journals from
The Company of Biologists